跳至主要内容
临床试验/ACTRN12615001238561
ACTRN12615001238561已完成未知

To determine the feasibility of cardiac MRI, echocardiography and serum biomarkers in detecting both early and later cardiac dysfunction in cancer patients after exposure to chemotherapy and/or radiotherapy.

iverpool Hospital0 个研究点目标入组 44 人开始时间: 2015年11月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Cohort A – breast cancer patients
  • (i) Aged greater than or equal to 18 years or older
  • (ii) Histologically confirmed diagnosis of invasive breast carcinoma
  • (iii) Receiving any anthracycline-containing breast cancer treatment regimen, including any adjuvant trastuzumab therapy AND going on to receive adjuvant left breast +/- loco-regional nodal radiotherapy, OR
  • (iv) Receiving adjuvant left breast +/- loco-regional nodal radiotherapy alone (without chemotherapy).
  • Acceptable radiotherapy regimens for Cohort A patients include:
  • a)50Gy in 25 daily fractions +/- 10-16Gy tumour bed boost, over 5-6 weeks
  • b)42.4Gy in 16 daily fractions +/- 10Gy tumour bed boost, over 3-4 weeks
  • Cohort B – Non Hodgkin (NHL) Hodgkin lymphoma (HL) and leukaemia patients
  • (i) Aged greater than or equal to 18 years or older
  • (ii) Histologically confirmed diagnosis of lymphoma
  • (iii) Receiving any anthracycline-or alkylator-containing chemotherapy regimen (eg. R-CHOP for NHL patients and ABVD for HL patients) and/or
  • (iv) Receiving definitive or adjuvant (post-chemotherapy) radiotherapy (dose greater than or equal to 20Gy) encompassing the mediastinum (ie. including cardiac structures)
  • Acceptable radiotherapy regimens for Cohort B patients include:
  • *Dose ranges from 20-40Gy in 1.5-2Gy daily fractions, over 2-4 weeks
  • Cohort C – other intra-thoracic/upper gastrointestinal malignancy patients (eg oesophageal/other eg thymoma)
  • (i) Aged greater than or equal to 18 years or older
  • (ii) Histologically confirmed intra-thoracic or upper gastrointestinal malignancy
  • (iii)Receiving any neoadjuvant - and/or adjuvant or concurrent chemotherapy regimen and
  • (iv)Receiving definitive or adjuvant radiotherapy (dose greater than or equal to 20Gy) encompassing the mediastinum (ie including cardiac structures)

排除标准

  • (i) any contraindication to cardiac MRI (i.e. shrapnel, metallic implants/clips, pacemaker or defibrillator);
  • (ii) severe claustrophobia;
  • (iii) an estimated glomerular filtration rate of less than 50 mL/min/1.732;
  • (iv) pregnancy or breast feeding;
  • (v) documented distant metastases from their known primary cancer;
  • (vi) patients receiving cancer treatment with palliative intent
  • (vii) planned or current use of other targeted biological therapies that can potentially cause cardiotoxicity (i.e. lapatinib)
  • (viii) Pre-existing symptomatic Heart Failure (NYHA Class III or IV).
  • (ix) Recent acute coronary syndrome (myocardial infarction, unstable angina) within the last six months
  • (x) Recent coronary revascularization (percutaneous coronary intervention or coronary bypass surgery) within six months
  • (xi) Permanent atrial fibrillation
  • (xii) Prosthetic breast implants that preclude echocardiography examination

研究者

发起方
iverpool Hospital

相似试验